Jidinum

Sitagliptin, the active ingredient in Jidinum, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control. GNH USA supplies Jidinum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder that requires long‑term glucose control. - Type 2 diabetes mellitus: improves fasting and post‑prandial blood glucose levels. - Adjunct to diet and exercise: helps patients reach target HbA1c when lifestyle measures alone are insufficient. - Combination therapy: can be combined with metformin, sulfonylureas or insulin to enhance overall glycaemic control.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient, mild to moderate intensity. - Upper respiratory tract infection: symptoms of cough, sore throat, or congestion. - Nausea: occasional mild stomach upset.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain that may require immediate medical attention. - Severe hypersensitivity reactions: including rash, angioedema, or anaphylaxis. - Bullous pemphigoid: a rare autoimmune blistering skin disorder.

Before initiating sitagliptin therapy, clinicians should consider several safety aspects. - Renal function: assess creatinine clearance and adjust dose in moderate to severe impairment. - Pancreatitis history: monitor for abdominal pain and discontinue if pancreatitis is suspected. - Concomitant hypoglycaemic agents: evaluate risk of additive hypoglycaemia, especially with insulin or sulfonylureas. - Elderly patients: start at the lowest effective dose and monitor tolerability. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, requiring clinical attention.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase sitagliptin plasma concentrations. - Co‑administration with insulin: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Sulfonylureas (e.g., glipizide): may potentiate hypoglycaemic effect. - Diuretics (e.g., thiazides): can affect glucose homeostasis, requiring closer monitoring. - Rifampin: may reduce sitagliptin exposure, potentially diminishing efficacy.